Relative lesion detection ability of Tc-99m HMDP and Tc-99m MDP: concise communication.
To compare the efficacy of Tc-99m HMDP and Tc-99m MDP to define skeletal lesions, 28 adult patients were examined in a double-blind, randomized, crossover study. Each patient was imaged with both agents over a period of 7-14 days. Both quantitative and qualitative evaluations were performed on the resulting images. Both agents detected the same number of skeletal lesions, and the number of lesions detected was the same whether the imaging was performed 2 or 4 hr after injection. Relative uptake of the tracer in the lesion relative to normal bone was also the same for both agents. Lesions were easier to see at 4 hr after injection than at 2 hr, presumably because soft-tissue levels were lower. Retention of tracer in bone compared with soft tissue was greater, and image quality was judged to be better, with Tc-99m HMDP than with Tc-99m MDP.
D000328:Adult; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002986:Clinical Trials as Topic; D004164:Diphosphonates; D004311:Double-Blind Method; D006801:Humans; D011877:Radionuclide Imaging; D013667:Technetium; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives; D013997:Time Factors
D004164:Diphosphonates; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D013667:Technetium; D013669:Technetium Tc 99m Medronate